Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast for prevention of amikacin-induced nephrotoxicity in children
IRCT20250202064597N1Phase 3Recruiting
- Sponsor
- Babol University of Medical Sciences
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of montelukast in drug-induced nephropathy (DIN), sponsored by Babol University of Medical Sciences. Started Mar 2026; status: recruiting.
02
Drugs
montelukast
03
Conditions
drug-induced nephropathy (DIN)
Beyond the preview
Go deeper on IRCT20250202064597N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250202064597N1.